CVS Settles With FTC Over Drug Rebates and TrumpRx
CVS Health has finalized a settlement with the FTC to curb the use of after-market rebates and count TrumpRx purchases toward patient deductibles. The agreement aims to lower drug costs and includes a monthly twenty-five dollar cap on out-of-pocket insulin payments for members.
X24 PerspectiveRelated Assets:
X24 Perspective